Sabrina Oliveira

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5272701/sabrina-oliveira-publications-by-year.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	3,215 citations	31 h-index	56 g-index
71 ext. papers	3,788 ext. citations	6.6 avg, IF	5.4 L-index

#	Paper	IF	Citations
66	In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates.. *Methods in Molecular Biology*, **2022**, 2451, 505-520	1.4	
65	Conjugation of IRDye Photosensitizers or Fluorophores to Nanobodies.. *Methods in Molecular Biology*, **2022**, 2451, 495-503	1.4	
64	Investigation of the Therapeutic Potential of Nanobody-Targeted Photodynamic Therapy in an Orthotopic Head and Neck Cancer Model.. *Methods in Molecular Biology*, **2022**, 2451, 521-531	1.4	
63	Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification.. *Methods in Molecular Biology*, **2022**, 2451, 481-493	1.4	
62	Assessment of the In Vivo Response to Nanobody-Targeted PDT Through Intravital Microscopy.. *Methods in Molecular Biology*, **2022**, 2451, 533-545	1.4	
61	Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy.. *Methods in Molecular Biology*, **2022**, 2451, 547-556	1.4	
60	Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. *Biomolecules*, **2021**, 11,	5.9	1
59	What NIR photodynamic activation offers molecular targeted nanomedicines: Perspectives into the conundrum of tumor specificity and selectivity. *Nano Today*, **2021**, 36,	17.9	8
58	Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. *Theranostics*, **2021**, 11, 9022-9037	12.1	4
57	Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?. *Theranostics*, **2021**, 11, 3882-3897	12.1	1
56	Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature **2021**, 175-186		
55	Nanobody-targeted photodynamic therapy for the treatment of feline oral carcinoma: a step towards translation to the veterinary clinic. *Nanophotonics*, **2021**, 10, 3075-3087	6.3	2
54	Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. *Theranostics*, **2021**, 11, 5525-5538	12.1	15
53	Gold Nanoclusters: Imaging, Therapy, and Theranostic Roles in Biomedical Applications.. *Bioconjugate Chemistry*, **2021**,	6.3	10
52	Correlation between in vitro stability and pharmacokinetics of poly(ε-caprolactone)-based micelles loaded with a photosensitizer. *Journal of Controlled Release*, **2020**, 328, 942-951	11.7	4
51	EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy. *Molecular Pharmaceutics*, **2020**, 17, 1276-1292	5.6	23
50	Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging. *Theranostics*, **2020**, 10, 2436-2452	12.1	22

49	Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations. *Journal of Clinical Medicine*, **2020**, 9,	5.1	27
48	Stacked Poly(caprolactone)--poly(ethylene glycol) Micelles Loaded with a Photosensitizer for Photodynamic Therapy. *Pharmaceutics*, **2020**, 12,	6.4	1
47	The Potential of Nanobody-Targeted Photodynamic Therapy to Trigger Immune Responses. *Cancers*, **2020**, 12,	6.6	14
46	Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. *Journal of Controlled Release*, **2020**, 323, 269-281	11.7	24
45	Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. *Cancers*, **2020**, 12,	6.6	5
44	Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions. *Nanomaterials*, **2020**, 10,	5.4	7
43	Dithiolane-Crosslinked Poly(caprolactone)-Based Micelles: Impact of Monomer Sequence, Nature of Monomer, and Reducing Agent on the Dynamic Crosslinking Properties. *Macromolecules*, **2020**, 53, 7009-7024	5.5	4
42	Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells. *Molecular Pharmaceutics*, **2019**, 16, 3145-3156	5.6	40
41	VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells. *Antibodies*, **2019**, 8,	7	17
40	Imaging of Tumor Spheroids, Dual-Isotope SPECT, and Autoradiographic Analysis to Assess the Tumor Uptake and Distribution of Different Nanobodies. *Molecular Imaging and Biology*, **2019**, 21, 1079-1088	3.8	17
39	Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. *Journal of Clinical Medicine*, **2019**, 8,	5.1	40
38	Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization. *Molecular Pharmaceutics*, **2019**, 16, 1633-1647	5.6	38
37	Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature. *Journal of Porphyrins and Phthalocyanines*, **2019**, 23, 1229-1240	1.8	9
36	Insights into maleimide-thiol conjugation chemistry: Conditions for efficient surface functionalization of nanoparticles for receptor targeting. *Journal of Controlled Release*, **2018**, 282, 101-109	11.7	58
35	Epidermal growth factor receptor (EGFR) density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines. *Lasers in Surgery and Medicine*, **2018**, 50, 513-522	3.6	14
34	Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. *Clinical Cancer Research*, **2017**, 23, 2730-2741	12.9	152
33	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. *Cancer Research*, **2017**, 77, 623-631	10.1	30
32	Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. *Cancers*, **2017**, 9,	6.6	489

31	Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors. *Frontiers in Immunology*, **2017**, 8, 1287	8.4	105
30	Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. *EJNMMI Research*, **2016**, 6, 14	3.6	40
29	Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. *Molecular Imaging and Biology*, **2016**, 18, 535-44	3.8	45
28	Site-specific conjugation of single domain antibodies to liposomes enhances photosensitizer uptake and photodynamic therapy efficacy. *Nanoscale*, **2016**, 8, 6490-4	7.7	29
27	EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. *Journal of Controlled Release*, **2016**, 229, 93-105	11.7	101
26	Nanobody-based cancer therapy of solid tumors. *Nanomedicine*, **2015**, 10, 161-74	5.6	155
25	Characterization and evaluation of the artemis camera for fluorescence-guided cancer surgery. *Molecular Imaging and Biology*, **2015**, 17, 413-23	3.8	33
24	Nanobody-targeted photodynamic therapy for oncology. *Photodiagnosis and Photodynamic Therapy* , **2015**, 12, 339	3.5	2
23	Capillary electrophoresis-based assessment of nanobody affinity and purity. *Analytica Chimica Acta*, **2014**, 818, 1-6	6.6	17
22	Nanobody-photosensitizer conjugates for targeted photodynamic therapy. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2014**, 10, 1441-51	6	68
21	Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody. *International Journal of Cancer*, **2014**, 134, 2663-73	7.5	66
20	Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 1718-29	8.8	92
19	Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways. *Molecular Pharmaceutics*, **2013**, 10, 3717-27	5.6	22
18	Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. *Breast Cancer Research and Treatment*, **2013**, 140, 263-72	4.4	19
17	Targeting tumors with nanobodies for cancer imaging and therapy. *Journal of Controlled Release*, **2013**, 172, 607-17	11.7	146
16	Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. *Biomaterials*, **2013**, 34, 1255-60	15.6	97
15	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. *Journal of Controlled Release*, **2012**, 159, 281-9	11.7	69
14	A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. *EJNMMI Research*, **2012**, 2, 50	3.6	43

List of Publications

13	Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti-Epidermal Growth Factor Receptor Nanobody. *Molecular Imaging*, **2012**, 11, 7290.2011.00025	3.7	119
12	Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. *Molecular Imaging*, **2012**, 11, 33-46	3.7	80
11	Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. *Journal of Controlled Release*, **2011**, 151, 183-92	11.7	81
10	Reprint of "Nanobody--shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". *Journal of Controlled Release*, **2011**, 153, 93-102	11.7	25
9	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. *Journal of Controlled Release*, **2010**, 145, 165-75	11.7	99
8	Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. *Drug Discovery Today*, **2010**, 15, 102-14	8.8	41
7	Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. *Current Cancer Drug Targets*, **2009**, 9, 748-60	2.8	140
6	Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. *Current Pharmaceutical Design*, **2008**, 14, 3686-97	3.3	37
5	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. *International Journal of Pharmaceutics*, **2007**, 331, 211-4	6.5	127
4	Sensitive spectroscopic detection of large and denatured protein aggregates in solution by use of the fluorescent dye Nile red. *Journal of Fluorescence*, **2007**, 17, 181-92	2.4	63
3	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. *Biochimica Et Biophysica Acta - Biomembranes*, **2007**, 1768, 1211-7	3.8	80
2	Targeted delivery of siRNA. *Journal of Biomedicine and Biotechnology*, **2006**, 2006, 63675		51
1	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. *Expert Opinion on Biological Therapy*, **2006**, 6, 605-17	5.4	47